<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133444</url>
  </required_header>
  <id_info>
    <org_study_id>012742</org_study_id>
    <nct_id>NCT01133444</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition</brief_title>
  <official_title>Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck &amp; Co., Propecia Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of Dr.
      Reddy's Laboratories, Ltd. and Merck &amp; Co. (Propecia®)

      1 mg finasteride tablets under fasting conditions following administration of a 3 mg dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description : The study was conducted as an open-label, randomized, single-dose,
      2-way crossover, relative bioavailability study performed on 24 healthy adult male volunteers
      and 2 alternates. A total of 24 subjects completed the clinical phase of the study. In each
      period, subjects were housed from the evening before dosing until after the 36-hour blood
      draw. Single oral 3 mg doses were separated by a washout period of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Finasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finasteride tablets 1 mg of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propecia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propecia 1 mgTablets of Merck &amp; Co.,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
    <description>Finasteride tablets 1 mg</description>
    <arm_group_label>Finasteride</arm_group_label>
    <arm_group_label>Propecia</arm_group_label>
    <other_name>Propecia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

        History or presence of significant:

        • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,
        immunologic, dermatologic, neurologic or psychiatric disease.

        In addition, history or presence of:

          -  alcoholism or drug abuse within the past year;

          -  hypersensitivity or idiosyncratic reaction to finasteride or any other 5-a reductase
             inhibitor.

        Subjects who have been on an abnormal diet (for whatever reason) during the 28 days
        preceding the study.

        Subjects who, through completion of the study, would have donated in excess of:

          -  500 mL of blood in 14 days, or

          -  500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator),

          -  1000 mL of blood in 90 days,

          -  1250 mL of blood in 120 days,

          -  1500 mL of blood in 180 days,

          -  2000 mL of blood in 270 days,

          -  2500 mL of blood in 1 year. Subjects who have participated in another clinical trial
             within 28 days prior to the first dosing.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Morelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Cohen street, saint-laurent, montreal (quebec)</city>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. Manager-Research and Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence,Finasteride,Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

